Skip to main content
Top
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

miR-141 as potential suppressor of β-catenin in breast cancer

Authors: Nairi Abedi, Samira Mohammadi-Yeganeh, Ameneh Koochaki, Fariba Karami, Mahdi Paryan

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Triple negative breast cancer (TNBC) is well known for its heterogeneous features and lack of targeted therapy. A variety of cell signaling pathways have been linked to the initiation and progression of these tumors where canonical Wnt signaling is one of the main candidate pathways. Considering past literatures on this matter and negative reports regarding mutations in β-catenin gene (CTNNB1), we focus our attention to another level of gene expression control level, microRNAs (miRNAs). For proper miRNA target detection, we utilized bioinformatics as a relatively new and reliable tool for miRNA: mRNA prediction. MDA-MB-231 (invasive breast cancer) and MCF-10A (normal breast) cell lines were chosen as models. We used different bioinformatic tools such as TargetScan, miRanda, etc. For miRNA targeting CTNNB1-3´UTR confirmation, luciferase assay was carried out. miRNA expression was induced in cell lines through viral constructs expressing desired miRNA. Quantitative real-time PCR was performed for the measurement of expression levels of selected miRNA and target gene. miR-141 was selected via expanded search among various bioinformatic tools. miR-141 expression level was downregulated in MDA-MB-231 cell line, and CTNNB1 gene expression was upregulated. After transduction with viral construct, miR-141 expression was elevated in both cell lines, and gene expression was notably decreased. β-Catenin can be considered as one of the main players in these tumors’ pathogenesis. Also, it is the potential target of miR-141, in which its downregulation was detected in cell lines, and can be considered as a promising new targeted approach toward TNBC.
Literature
3.
go back to reference Avery-Kiejda KA et al. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 2014;14(1):51.CrossRefPubMedPubMedCentral Avery-Kiejda KA et al. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 2014;14(1):51.CrossRefPubMedPubMedCentral
4.
go back to reference Gasparini P et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5(5):1174.CrossRefPubMedPubMedCentral Gasparini P et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5(5):1174.CrossRefPubMedPubMedCentral
5.
go back to reference Schneider BP et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.CrossRefPubMed Schneider BP et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.CrossRefPubMed
6.
go back to reference Kamdje AHN et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–56.CrossRef Kamdje AHN et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–56.CrossRef
8.
go back to reference Chu EY et al. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development. 2004;131(19):4819–29.CrossRefPubMed Chu EY et al. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development. 2004;131(19):4819–29.CrossRefPubMed
9.
go back to reference Khramtsov AI et al. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20.CrossRefPubMedPubMedCentral Khramtsov AI et al. Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20.CrossRefPubMedPubMedCentral
10.
go back to reference Hatsell S et al. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8(2):145–58.CrossRefPubMed Hatsell S et al. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2003;8(2):145–58.CrossRefPubMed
11.
go back to reference Cai J et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013;123(2):566.PubMedPubMedCentral Cai J et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013;123(2):566.PubMedPubMedCentral
12.
go back to reference Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126–39.CrossRefPubMed Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126–39.CrossRefPubMed
13.
go back to reference Cai Y et al. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147–54.CrossRefPubMed Cai Y et al. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147–54.CrossRefPubMed
14.
go back to reference Winter J et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228–34.CrossRefPubMed Winter J et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228–34.CrossRefPubMed
15.
go back to reference Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390–4.CrossRefPubMed Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66(15):7390–4.CrossRefPubMed
16.
go back to reference Nana-Sinkam SP, Fabbri M, Croce CM. MicroRNAs in cancer: personalizing diagnosis and therapy. Ann N Y Acad Sci. 2010;1210(1):25–33.CrossRefPubMed Nana-Sinkam SP, Fabbri M, Croce CM. MicroRNAs in cancer: personalizing diagnosis and therapy. Ann N Y Acad Sci. 2010;1210(1):25–33.CrossRefPubMed
17.
go back to reference Faryal R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 2011;12:3175–80.PubMed Faryal R. Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 2011;12:3175–80.PubMed
18.
19.
go back to reference Al-Rajab M. and J. Lu, Bioinformatics: an overview for cancer research. 2012. Al-Rajab M. and J. Lu, Bioinformatics: an overview for cancer research. 2012.
20.
go back to reference Mount, D.W., Sequence and genome analysis. Bioinformatics: Cold Spring Harbour Laboratory Press: Cold Spring Harbour. 2004; 2. Mount, D.W., Sequence and genome analysis. Bioinformatics: Cold Spring Harbour Laboratory Press: Cold Spring Harbour. 2004; 2.
21.
go back to reference Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–71.PubMedPubMedCentral Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463–71.PubMedPubMedCentral
24.
go back to reference Xin F et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 2009;25(4):430–4.CrossRefPubMed Xin F et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 2009;25(4):430–4.CrossRefPubMed
25.
go back to reference Wang C et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31(1):58.CrossRefPubMedPubMedCentral Wang C et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31(1):58.CrossRefPubMedPubMedCentral
26.
go back to reference Mohammadi-Yeganeh S et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis. Mol Biol Rep. 2013;40(5):3665–74.CrossRefPubMed Mohammadi-Yeganeh S et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis. Mol Biol Rep. 2013;40(5):3665–74.CrossRefPubMed
27.
go back to reference Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013;11(1):280.CrossRefPubMedPubMedCentral Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013;11(1):280.CrossRefPubMedPubMedCentral
28.
go back to reference Esau C et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279(50):52361–5.CrossRefPubMed Esau C et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279(50):52361–5.CrossRefPubMed
Metadata
Title
miR-141 as potential suppressor of β-catenin in breast cancer
Authors
Nairi Abedi
Samira Mohammadi-Yeganeh
Ameneh Koochaki
Fariba Karami
Mahdi Paryan
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3738-y

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine